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who needed vasopressive support received the target dose. 
 Conclusion: Prescription of target IHD dose by single pool 
Kt/V urea resulted in suboptimal dialysis dose delivery in criti-
cally ill patients. Numerous patient-related and treatment-
immanent factors acting in concert reduced the delivered 
dose.  Copyright © 2007 S. Karger AG, Basel 
 Introduction 
 The increasing number of multi-morbid patients ad-
mitted to medical or surgical services has been accompa-
nied by a greater incidence of acute renal dysfunction in 
hospitalized patients. Despite its potential reversibility, 
the development of hospital-acquired acute renal failure 
(ARF) represents a major barrier for the recovery of the 
patient. Even small changes in renal function are associ-
ated with substantial increases in mortality and the out-
come of critically ill patients with ARF requiring acute 
renal replacement therapy has remained distressingly 
poor over the decades  [1] .
 It is not yet clear which strategies of renal replacement 
therapy provide the optimal choice to improve patient 
morbidity and mortality in ARF. Several studies have 
shown that more intensive provision of dialysis may im-
prove the survival of intensive care unit (ICU) patients 
with ARF  [2–4] . While both the minimally adequate as 
well as the optimal doses are unknown, it is clear that the 
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 Abstract 
 Background/Aims: Methods of intermittent hemodialysis 
(IHD) dose quantification in acute renal failure (ARF) are not 
well defined. This observational study was designed to eval-
uate the impact of disease activity on delivered single pool 
Kt/V urea in ARF patients.  Methods: 100 patients with severe 
ARF (acute intrinsic renal disease in 18 patients, nephrotoxic 
acute tubular necrosis in 38 patients, and septic ARF in 44 
patients) were analyzed during four consecutive sessions of 
IHD, performed for 3.5–5 h every other day or daily. Target 
IHD dose was a single pool Kt/V urea of 1.2 or more per dialysis 
session for all patients. Prescribed Kt/V urea was calculated 
from desired dialyzer clearance (K), desired treatment time 
(t) and anthropometric estimates for urea distribution vol-
ume (V). The desired clearance (K) was estimated from pre-
scribed blood flow rate and manufacturer’s charts of in vivo 
data obtained in maintenance dialysis patients. Delivered 
single pool Kt/V urea was calculated using the Daugirdas 
equation.  Results: None of the patients had prescription fail-
ure of the target dose. The delivered IHD doses were sub-
stantially lower than the prescribed Kt/V values, particularly 
in ARF patients with sepsis/septic shock. Stratification ac-
cording to disease severity revealed that all patients with iso-
lated ARF, but none with 3 or more organ failures and none 
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dose provided as estimated by urea kinetic modeling is 
often markedly lower than the prescribed dose  [5–11] . 
Evanson et al.  [6] found that although 49% of 40 ARF pa-
tients were prescribed a Kt/V of  ! 1.2, the Kt/V delivered 
was below this level in the majority of patients (70%). 
These data indicate that dialysis delivery is mostly sub-
optimal in ARF.
 There is no doubt that an inadequately prescribed di-
alysis dose results in delivery failure. Further reasons for 
the discrepancy between prescribed and delivered dialy-
sis in the setting of ARF are treatment-related factors 
(catheter dysfunction, recirculation, decreased dialyzer 
function)  [6–8, 11] . Whether or not demographic factors 
affect delivery of dialysis dose in the setting of ARF is not 
clear.
 This prospective cohort study examined the utility of 
single pool Kt/V urea (spKt/V urea ) for prescription of a tar-
get dose in 3 groups of patients with different causes of 
ARF. Severity of disease was identified as a factor that 
impeded effective delivery of prescribed dialysis in ARF 
patients.
 Patients and Methods 
 Study Design 
 Patients with severe ARF requiring intermittent hemodialysis 
(IHD) were eligible for enrolment in this prospective observa-
tional study during a period from 1997 to 2005. Patients were 
treated at the Department of Internal Medicine (Medizinische 
Klinik-Innenstadt) of the University of Munich or KfH Renal 
Centers in Munich-Laim or in Bad Reichenhall. Measurements of 
spKt/V were part of routine practice of renal replacement therapy 
for ARF in these centers. The investigator had no influence on the 
general medical care of the patients. No rigid alternate day or dai-
ly dialysis schedule was employed and treatment decisions were 
made on a day-to-day basis according to the individual patient’s 
needs. The study protocol was approved by the Institutional Re-
view Board of each participating site. Informed consent was ob-
tained from the patients or from their next of kin.
 Study Population 
 Patients were included in the study if they had ARF secondary 
to acute intrinsic renal disease, clinically diagnosed toxic acute 
tubular necrosis (ATN) or sepsis based on the criteria set by the 
American College of Chest Physicians  [12] . Exclusion criteria 
were participation in another clinical trial, pregnancy, organ 
transplantation, preexisting chronic renal insufficiency (based 
on history, abnormal ultrasound or urinalysis, elevated serum 
creatinine and/or a reduction in the calculated glomerular filtra-
tion rate prior to the acute disease), and isolated ultrafiltration for 
hypervolemia. Patients were also excluded when they had bleed-
ing disorders contradicting systemic heparin anticoagulation (ac-
tive gastrointestinal bleeding, recent surgery, thrombocytopenia 
or consumption coagulopathy) and concomitant therapy with 
plasmapheresis. Patients who had, or were at risk of, cerebral ede-
ma received continuous renal replacement therapies.
 Intermittent Hemodialysis 
 Each patient had 2 polyurethane dialysis catheters placed per-
cutaneously in two central veins, either femoral veins (length 25 
cm) or the internal jugular or the subclavian vein (length 15 or 20 
cm). Dialysis treatments were performed with machines that had 
volumetric ultrafiltration control (Fresenius MTS 2008 C, Frese-
nius, Homburg v.d. Höhe, Germany, or Gambro AK 200, Gam-
bro, Hechingen, Germany). Single-use polysulfone dialyzers (F 60 
Fresenius, Germany) and bicarbonate dialysate were used exclu-
sively. Blood flow rates ranged between 250 and 350 ml/min; the 
dialysate flow rate was set at 500 ml/min. The dialysis fluid met 
the microbiological standards of the European Pharmacopoeia of 
 ! 100 CFU/ml and  ! 0.25 endotoxin units/ml. IHD was performed 
according to the patient’s clinical status, the frequency ranged 
from alternate day to daily sessions.
 Clinical Data Acquisition 
 Baseline demographic characteristics were prospectively col-
lected from the patient’s hospital records. These included age, 
gender, body weight and height at admission. At commencement 
of IHD the cause of ARF (based on history, clinical investigation, 
renal ultrasound, urinalyses, blood parameters and/or kidney bi-
opsy) was acute renal disease (glomerulonephritis, vasculitis, tu-
bulointerstitial nephritis, atheroembolism) in 18 patients, neph-
rotoxic ATN (antibiotics, cytostatic drugs, contrast media, hemo-
globinuria and myoglobinuric disorders) in 38 patients, and 
sepsis/septic shock in 44 patients. The severity of illness in each 
patient was determined using the Acute Physiological and Chron-
ic Health Evaluation (Apache II) score before the first dialysis ses-
sion. The number of organ failures was calculated using the mul-
tiple systems organ failure score  [13] . ARF-related biochemical 
parameters such as blood urea nitrogen (BUN), serum creatinine 
levels, and urine volume were also recorded.
 Dialysis treatment data included the site of central venous 
catheter, intra-dialysis blood flow rates (documented at 30-min 
intervals), pre- and post-dialysis weight (measured by stand-on or 
chair scales in mobile patients and by bed scales in bedridden pa-
tients), duration of dialysis sessions, pre- and post-dialysis BUN, 
ultrafiltration rate, anticoagulation, post-dialysis judgment of di-
alyzer patency, mean arterial pressure prior to the hemodialysis 
session and need for pressor support (except renal dose of dopa-
mine). Blood samples were again drawn in 10 patients of each 
group 60 min after hemodialysis.
 Prescribed Dose of IHD 
 Before each treatment, a prescribed Kt/V was determined ac-
cording to the dialyzer manufacturer’s specifications, the in vivo 
clearance of urea (ml/min) was determined in maintenance di-
alysis patients, and the dialysis prescription time and the anthro-
pometric estimates of total body water (the urea volume distribu-
tion) according to the equation of Watson et al.  [14] . The desired 
clearance was estimated from prescribed blood flow and the man-
ufacturer’s charts of in vivo data. Patients in each etiologic ARF 
group were dialyzed with a projected spKt/V of 1.2 per session, 
which was derived from contemporary clinical practice guide-
lines which recommended a minimum delivered spKt/V of 1.2 for 
patients with ESRD  [15, 16] .
 Single Pool Kt/V urea in Acute Renal 
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 Delivered Dose of IHD 
 The pre-dialysis BUN sample was drawn from the femoral 
catheter immediately before dialysis. The post-dialysis BUN sam-
ple was obtained using the stop flow method (blood flow rate 
50–100 ml/min for 20 s). The delivered dialysis dose was assessed 
by spKt/V using the second-generation equation of Daugirdas 
 [17] :
 spKt/V = –ln(R – 0.008 t) + (4 – 3.5 R) UF/W
 where R is the post-BUN/pre-BUN dialysis ratio, t is the delivered 
dialysis time in hours, UF is the volume of fluid removal during 
dialysis in liters and W is the post-dialysis weight in kilograms.
 Calculation of Post-Dialysis Urea Rebound 
 Post-dialysis urea rebound (PDUR) was calculated as the per-
centage of the increase in serum urea levels at 60 min compared 
with urea levels immediately post-dialysis:
 PDUR = (urea after 60 min – urea post-dialysis)
                 ! 100/urea post-dialysis.
 Statistics 
 Data are presented as mean  8 SD or as percentage. For the 
demographic variables, an analysis of variance was used to evalu-
ate the continuous values, whereas Fisher’s exact test was used to 
evaluate the categorical variables. The Generalized Estimating 
Equation method statistical procedure for longitudinal data anal-
ysis with multiple observable vectors for the same subject was also 
used in the data analysis. This procedure is a repeated measures 
analysis for corrected dichotomous outcomes and a set of predic-
tors  [18] . All tests of significance were two-sided and differences 
were considered significant for p values of  ! 0.05. SAS version 6.12 
(SAS Institute, Inc., Cary, N.C., USA) was used for all analyses.
 Results 
 Characteristics of the Study Cohort 
 One hundred patients with ARF requiring IHD were 
selected for this observational study according to disease 
severity. Eighty (80%) of the patients were treated in the 
ICU, and of those, 50 patients were on ventilator therapy 
and 55 patients received vasopressors. Compared to body 
weight at admission patients with septic shock had a clin-
ically relevant and statistically significantly higher weight 
at the start of IHD (mean weight gain 8 kg).
 The patients with acute renal disease had isolated ARF, 
a lower severity of acute illness compared to other pa-
tients, a better survival (as judged by the in-hospital mor-
tality), but a significantly higher proportion of these pa-
tients needed dialysis at discharge. Septic patients were 
critically ill (59% with septic shock), had ARF as part of 
multiple organ failure syndrome with an excessive in-
hospital case mortality rate ( table 1 ).
 Characteristics of Hemodialysis Sessions 
 The prescription of IHD was similar in all groups of 
ARF patients; each patient had a prescribed target dose of 
a spKt/V of 1.2 or more per session ( table 2 ). All patients 
Table 1. Patient characteristics at admission, at start of dialysis 
and at discharge
Acute renal
disease
Toxic
ATN
Sepsis
Number of patients 18 38 44
At admission
Age, years 4788 5888 60813
Gender, m/f 12/6 23/15 24/20
Body weight, kg 74815 71813 65810
At start of IHD
BUN, mg/dl 76810 72816 80812
Creatinine, mg/dl 4.881.1 4.581.4 4.381.5
Oliguria, % 44 46 48
MAP, mm Hg 110810 105813 7888**
APACHE II 1082* 1983** 3283
Organs failing 180* 1.680.2** 3.180.3
Body weight, kg 75816 73812 73811
Outcome parameters
Hospital case fatality rate, % 6* 21** 70
Need for dialysis
after discharge, % 50* 3 0
Unless otherwise indicated, the data are mean 8 SD.
* p < 0.05 vs. nephrotoxic ATN and sepsis or vs. nephrotoxic 
ATN and acute renal disease; ** p < 0.05 vs. acute renal disease or 
sepsis.
Table 2. Prescribed and delivered spKt/V in the three ARF patient 
groups (mean 8 SD)
Acute renal 
disease
ATN Septic ARF
Blood flow rate, ml/min
Prescribed 271837 269834 269840
Delivered 268837 259825 264825
Duration of session, min
Prescribed 237831 215830 217827
Delivered 231829 219828 220825
spKt/Vurea
Prescribed 1.3680.17 1.2880.06 1.2880.07
Delivered 1.3180.10 1.1580.12 0.8980.04*
PDUR, % 1582 1781 2282
PDUR = Post-dialysis urea rebound.
* p < 0.05 vs. acute renal disease or toxic ATN.
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had two catheters in central veins, they all received hepa-
rin and there was no clotted dialyzer. Given the low pre-
dialysis blood pressure and the need for vasopressors, hy-
potensive episodes necessitating intervention (adminis-
tration of saline, reduction of ultrafiltration rate) were 
low, even in septic patients (5% acute renal disease vs. 7% 
ATN vs. 10% septic ARF, respectively). No dialysis ses-
sion was prematurely terminated. The three patient 
groups differed in the frequency of IHD per day (0.5 per 
day for acute renal disease, 0.7 per day for ATN, and 1.0 
per day for septic ARF). There were no statistically sig-
nificant differences in ultrafiltration rate per session 
(mean ultrafiltration rate was 1,765 ml/session for acute 
renal disease, 1,665 ml/session for the patient group with 
nephrotoxic ATN, and 1,825 ml/session for septic pa-
tients.
 Delivered IHD according to Disease Severity 
 There was no statistically significant difference be-
tween prescribed and delivered Kt/V in patients with 
acute renal disease. The delivered dialysis dose was sig-
nificantly lower than the prescribed KT/V in patients 
with ATN or septic ARF. Delivery failure was more pro-
nounced in patients with septic ARF ( tables 2 ,  3 ). The 
delivery of IHD dose was loosely correlated to the num-
ber of failing organs ( table 4 ) and none of the patients on 
vasopressor support reached the target dose of a spKt/
V urea of 1.2 ( table 4 ).
 Post-dialysis rebound tended to be higher in septic pa-
tients ( table 2 ).
 Discussion 
 There are two types of factors that give rise to under-
delivery of prescribed IHD dose as measured by spKt/
V urea in the setting of ARF: those pertaining to the patient 
and those related to the therapy itself. The data of this 
observational study highlight the complex interactions 
between the patient’s severity of acute illness and the de-
livery of the IHD dose. The greater inability to deliver the 
prescribed dose to critically ill patients with severe ARF 
is a new finding. The discrepancy between the present 
investigation and previous analyses may be well explained 
by substantial differences in the number of participants, 
the case mix of causes of ARF and the inclusion or exclu-
sion of patients with prescription failure  [6, 8] .
 SpKt/V urea is a generally accepted method to measure 
the delivered dose of dialysis in maintenance dialysis pa-
tients. However, the reliability and utility of the blood-
based simplified IHD quantification formula of urea ki-
netic modeling may be not the same in the setting of ARF 
as in ESRD as the fundamental assumptions of measure-
ment of spKt/V urea may be violated, at least in critically ill 
patients with ARF necessitating IHD. Measurements of 
spKt/V urea assumes steady-state urea nitrogen appear-
ance, constant dialyzer clearance at a given blood and 
dialysate flow rate, and a ‘well-mixed’ urea volume of dis-
tribution, identical to the total body water, with no com-
partmentalization of urea distribution. Due to the nature 
of an acute life-threatening illness; however, patients with 
severe ARF are rarely in a steady-state.
 Whereas delivered Kt/V urea values in patients with iso-
lated ARF were slightly lower than the prescribed Kt/
V urea values in analogy to maintenance dialysis patients, 
a substantial difference (by 30%) between the prescribed 
and delivered dialysis dose was found in critically ill pa-
Table 3. Delivery of target IHD dose in three ARF patient 
groups
Kt/Vurea 
<1.2 ≥1.2
Acute intrinsic renal disease 0 of 18 18 of 18
Toxic acute tubular necrosis 11 of 38 27 of 38
Septic ARF 44 of 44* 0 of 44
Values are the number of patients.
* p < 0.05 vs. acute renal disease or toxic acute tubular ne-
crosis.
Table 4. IHD dose delivered in three groups of ARF patients
stratified according to disease severity
Kt/Vurea 
<1.2 ≥1.2
Number of organs failing
1 0 of 35 35 of 35
2 10 of 20 10 of 20
3 or more 45 of 45* 0 of 45
Pressor support
No vasoactive drugs 0 of 45 45 of 45
Vasopressor 55 of 55 0 of 55
Values are the number of patients.
* p < 0.05 vs. acute renal disease or toxic ATN.
 Single Pool Kt/V urea in Acute Renal 
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tients with ARF. The discrepancy between the prescribed 
and delivered dose of IHD observed in the present study 
was not caused by the failure to prescribe a Kt/V urea of 
 1 1.2.
 There is compelling evidence that volume expansion, 
typically seen in ICU patients who suffer from shock and 
multi-organ insults, represents a major factor contribut-
ing to the under-delivery of the prescribed IHD dose. 
This expansion of body water compartments is the con-
sequence of therapeutic volume resuscitation in the set-
ting of increased capillary permeability often seen in pa-
tients with sepsis/septic shock. The expansion is usually 
not subtle and may sometimes exceed 30–40 liters in a 
given patient  [19] . This distortion of body habitus obvi-
ously renders invalid the calculation of body water from 
anthropometric measurements derived from measure-
ments in normal healthy adults. Himmelfarb et al.  [20] 
showed in critically ill patients with ARF that determina-
tions of total body water by anthropometric measure-
ments (Watson, Hume-Weyer, Chertow formulae) yield-
ed significantly lower measures compared to total body 
water values determined by physiological formulae or 
bioelectrical impedance analysis. Moreover, V deter-
mined by formal urea kinetic modeling or by isotope 
methods was reported to average 65 or 64.3% of body 
weight in critically ARF patients  [21, 22] . In support of 
the over-hydration factor, Kanagasundaram et al.  [10] 
found that the ratio of modeled to anthropometric urea 
volume of distribution was highest at the point of initiat-
ing dialysis, and this diminished over time as regular di-
alysis therapy was applied. Thus, attempts to use formu-
las such as Watson’s (used in this study) for the prescrip-
tion of dialysis will greatly overestimate the delivered 
dose.
 Secondly, critically ill ARF patients have high protein 
catabolic rates ( 1 1.5 g/kg/day) and substantial nitrogen 
deficits (6 g/day). This catabolic state, which can vary 
from hour to hour, may affect the actual delivered dose 
of dialysis by resulting in accelerated intra-dialytic urea 
generation that needs to be taken into account when mea-
suring blood-based methods of IHD dosing. However, 
Evanson et al.  [7] demonstrated that the patient’s cata-
bolic rates, as estimated by the urea nitrogen appearance, 
had no significant effect on the delivered Kt/V. Other po-
tential problems with delivery of dialysis dose include 
post-hemodialysis BUN rebound and cardiopulmonary 
recirculation which may influence the post-treatment 
BUN levels. These factors probably had little influence on 
the results of this study because firstly, all angio-accesses 
used were venovenous and therefore there was no cardio-
pulmonary recirculation. Secondly, the stop-flow meth-
od with timed blood sample collection was developed to 
diminish the effects of post-dialysis BUN rebound. There 
was no significant difference between the time of collec-
tion (20 s) among the three etiologic groups of ARF.
 The second potential stumbling block with blood-de-
rived clearance-based methods relates to IHD treatment-
related factors: the nature of the angio-access and the 
need for anticoagulation. Access recirculation and poor 
blood flows with inadequate catheter function are inher-
ent limitations of acute IHD and have a negative impact 
on the spKt/V urea delivered. Numerous clinical studies 
have demonstrated that the frequency of these drawbacks 
of temporary venous catheters depends on the site of in-
sertion, technique of insertion (tunneled vs. convention-
al) and the length of catheter used. Liangos et al.  [9] de-
scribed a relation between delivered dialysis dose and the 
use of two-lumen femoral catheters. These authors found 
a high blood flow rate and a decrease in urea reduction 
ratio with femoral compared to non-femoral catheters. 
Klouche et al.  [11] showed that tunneled two-lumen fem-
oral catheters were associated with higher delivered spKt/
V urea than conventional (not-tunneled) two-lumen cath-
eters. In the present study, double-lumen catheters were 
not used, each patient had two catheters – a right-sided 
thoracic and a femoral catheter of 25 cm length.
 The other problem area of treatment-associated barri-
ers relates to the function of the hemodialyzer. Severe 
bleeding diathesis is frequently present in critically ill pa-
tients. Consequently, for many patients heparin-free di-
alysis is prescribed for ARF. Heparin-free dialysis has 
been shown to cause a decreased patent fiber bundle vol-
ume despite no significant change in arterial or venous 
circuit pressure. In fact, there is concern that compro-
mised dialyzer function during heparin-free dialysis af-
fects treatment delivery in ARF patients treated with IHD 
 [6] . Patients with risk for bleeding were excluded from the 
present study, all patients received systemic heparin. Fi-
nally, the calculated dialysis dose may not match the pre-
scribed dose due to the fact that in vivo clearances are 
10–15% lower than in vitro  [23] . However, in this series 
the manufacturers of the dialyzers provided in vivo data 
from maintenance patients so that in vitro data did not 
need to be used. Patient hemodynamic instability may 
result in shorter treatments. Improved techniques of in-
termittent dialysis including variable sodium, calcium 
and ultrafiltration modeling combined with modifica-
tions of dialysate buffer or temperature allow safe therapy 
in the great majority of critically ill patients. In the pres-
ent study, there was only a 10% incidence of significant 
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hypotension in septic ARF patients. None of the sessions 
was prematurely terminated; blood flow rates were not 
changed during sessions with hypotensive episodes.
 Practical difficulties to deliver dialysis dose in ARF 
patients may relate to intercompartmental urea disequi-
librium, which can be conceptualized as delayed entrance 
of urea from relatively inaccessible body pools into the 
blood. This compartmentalization phenomenon may 
have several clinical implications. First, it is responsible 
for the well-described rebound in plasma urea concentra-
tion that occurs after dialysis, during which time the sol-
ute disequilibrium disappears. Most importantly, dis-
equilibrium in urea distribution reduces the overall ef-
fective urea removal and overestimates delivered dialysis 
dose. Traditionally, many investigators have assumed 
that urea is distributed in the extracellular and intracel-
lular spaces, with relative sequestration into the latter. 
However, Daugirdas and Schneditz  [24] proposed that 
the regional blood flow differences can cause the afore-
mentioned disequilibrium. In this model, urea disequi-
librium is related to the degree of mismatch between 
blood supply and urea content in different body compart-
ments. Specifically, although skeletal muscle is a large 
reservoir for both water and urea, in hypotensive, periph-
erally vasoconstricted, critically ill patients, blood supply 
to this compartment is relatively low. This mismatch may 
be worsened in septic ICU patients who have further im-
pairment of skeletal muscle perfusion due to vasopressor 
dependence. Currently, the effect of compartmentaliza-
tion of urea on IHD dose delivery has not been fully in-
vestigated in the setting of critically ill patients with ARF, 
but it may not be as great as thought. Kanagasundaram 
et al.  [10] determined average post-dialysis rebound (cor-
rected for urea generation) to be only 11.4% which is sim-
ilar to the values of 11.6% for maintenance hemodialysis 
outpatients using catheters. Moreover, measurements of 
the intercompartmental mass transfer coefficient, anoth-
er measure of solute disequilibrium, provided only mar-
ginal support for urea disequilibrium.
 In summary, this study provides evidence for the im-
portance of patient-related characteristics such as the se-
verity of acute underlying disease in affecting the deliv-
ered dose of IHD, as measured by spKt/V urea . A number 
of factors may reduce the delivered dose to critically ill 
patients; no factor actually increases it, so the error will 
always be in the direction of a lower delivered dose when 
compared with the prescribed dose. 
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Announcement
The International Society for Hemodialysis (ISHD) will present the 2008 ISHD Beld-
ing Scribner Trailblazer Award to Dr. Jack Cimino on March 1, 2008 at the Annual Di-
alysis Conference (sponsored by the University of Missouri at Columbia, Mo. and to be 
held at the Rosen Shingle Creek Resort in Orlando, Fla., USA).
Dr. Cimino is honored for his exemplary, pioneer work on the development of an 
 arteriovenous fistula for the purpose of dialysis access. 
For more information please visit dialysis@health.missouri.edu.
Jointly sponsored by the Annual Dialysis Conference and the International Society 
for Hemodialysis, a 1-day symposium titled ‘The Renaissance of Home Hemodialysis: 
Lessons from the World Over’ will be held on March 1, 2008 at the Rosen Shingle Creek 
Resort, Orlando, Fla., USA. 
Please visit dialysis@health.missouri.edu for more information. 
The 17th International Vicenza Course on Hemodialysis and the 1st Congress of the 
International Society for Hemodialysis will be jointly sponsored by the Department of 
Nephrology, Dialysis and Transplantation, St. Bortolo Hospital, Vicenza, Italy, and the 
International Society for Hemodialysis.
The meeting will take place on June 3–6, 2008 at the Congress Center Ente Fiera, 
 Vicenza, Italy.
All are welcome to attend. Information can be obtained from 
www.nefrologiavicenza.it or www.vicenzanephrocourses.com.
